Medication Errors in Neonates
Potential ADE (adverse drug event) rate is 3× Higher Than Adults1
Dose Errors in Pediatrics
10-fold “Decimal Point Errors” are more common in children 2
Reduction in Errors
When transitioning from manual compounding to preparation with technological controls 3
Pediatric Compounding Errors
Pediatric & neonatal units report 14–26% error rates 4
Children are not small adults. Narrow therapeutic windows, weight-based dosing, and underdeveloped immune systems mean that a miscalculated dose or an undetected contaminant can have consequences far greater than in adult care.
Mundus Neo address both risks, precision-guided dosing and a validated closed system that prevents microbial contamination at every step of the compounding process.
From the makers of the #1 CSTD trusted by pharmacists nationwide for over seven consecutive years5. EQUASHIELD NHD accessories are built to the same uncompromising standard of precision, safety, and reliability. Every element of EQUASHIELD Mundus Neo accessories are designed for repeatability and speed without leaks.
Designed to maintain aseptic technique and prevent microbial contamination, they help ensure a sterile fluid pathway throughout the compounding process. They also help keep the environment free of medication residues, minimizing unnecessary exposure to medications for both healthcare professionals and the surrounding environment.
Featuring a septum-to-septum double-membrane design, they support a safer and cleaner compounding process so you can stay focused on what matters most: patient care.
Manual transcription introduces errors. Mundus Neo removes this step by processing compounding orders electronically with no manual entry.
Preparation data, verification records, and compliance documentation are generated automatically, providing a complete audit trail without added administrative work.
Minimizes contamination risk
* Product features and specifications are subject to change without notice. Currently available in select international markets. U.S. regulatory clearance in progress.
